TTFields Plus Temozolomide vs Temozolomide on Glioblastoma
This randomized trial compares the effects of tumor-treating fields plus temozolomide vs temozolomide alone on progression-free and overall survival in patients with glioblastoma who had undergone resection or biopsy and radiochemotherapy. Read the article at: http://ja.ma/2BhJSoU.
Видео TTFields Plus Temozolomide vs Temozolomide on Glioblastoma канала JAMA Network
Видео TTFields Plus Temozolomide vs Temozolomide on Glioblastoma канала JAMA Network
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Disparities in COVID-19 Testing and Infection Across Language Groups in SeattleTransitions in JAMA PsychiatryReal-Time Artificial Intelligence–Guided Ultrasonography With Quality and Result FeedbackOral Antibiotics vs IV and Oral Antibiotics for Uncomplicated AppendicitisThe Top JAMA Network Articles of 2018Prevalence of Immunosuppression Among US AdultsAI and Clinical PracticeCharacteristics Associated With Use of Direct Scheduling in Primary Care PracticesHypertension and DementiaUltrasound-Guided Popliteal Vein Access in Prone PatientsWeaving Indigenous Textile Art Into Cardiac DevicesDemonstration of the Epley Self-maneuver for a Right Posterior Canal CanalithiasisTranscatheter Aortic Valve-in-Valve Procedure After Bioprosthetic Valve FailureClinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineaeDynamic View of the Floating Retinal VeinsFollow-up and Outcomes Among Medicare Beneficiaries After Emergency Department DischargeModeling Contact Tracing Strategies for #COVID19Financial Incentives for Weight Loss in Men With ObesityDo Stay-at-Home Orders Reduce COVID-19 Infection Rates?Left Ventricular NoncompactionReflectance Confocal Microscopy Criteria for Squamous Cell Carcinomas and Actinic Keratoses